RCC unpacked- Navigating real-world cases with clinical precision post progression on first line therapy

1. What is the first step in the clinical algorithm for selecting first-line treatment in mRCC?

2. Many patients with aRCC will not receive later lines of therapy in real- world practice, only

3. The IMDC classification categorises patients into which three risk groups?

4. Which treatment approach is generally preferred when rapid tumour shrinkage s required?

5. According to ESMO guidelines, which type of regimen is considered the standard of care for first-line advanced clear-cell RCC?

6. In the treatment of advanced RCC and metastatic clear cell RCC.  The ESMO guidelines algorithm recommends monotherapy______,________,________, _________if immune checkpoint inhibitors are contraindicated or not available.

7. Which biological feature is associated with heightened sensitivity to PD-1-based combination therapies?

8. Which first-line monotherapy TKI has the strongest evidence in papillary RCC?

9. Rare aggressive subtypes such as collecting duct / SMARCB1-deficient RCC are often treated with______.

10. In the phase 2 CABOSUN trial, Cabozantinib was compared to Sunitinib and median progression free survival by investigator assessment was_____ months for Cabozantinib vs ______months for Sunitinib (HR 0.66, 95% CI 0.46- 0.95, P less than 0.012).